Literature DB >> 15801487

How representative are the surveillance, epidemiology, and end results (SEER) program cancer data of the United States?

Ray M Merrill1, Kirk A Dearden.   

Abstract

OBJECTIVE: Data from the 11 Surveillance, Epidemiology, and End Results tumor registries cover 14% of the U.S. population and are often used to provide national estimates of cancer incidence and survival. Cancer mortality data for the U.S. and for SEER are compared to assess the representation of SEER to the U.S.
METHODS: Comparisons between US and SEER cancer mortality were made for 16 of the leading causes of cancer death. Cancer site-specific comparisons were also made by race and sex. In addition, tobacco-related cancers were considered. Analyses were performed for the years when all 11 SEER registries were included in the SEER program. Poisson regression was used to estimate site-specific cancer mortality rate ratios between the U.S. and SEER.
RESULTS: Cancer site-specific mortality rates derived from SEER data tend to under-represent the U.S. cancer mortality experience for white males and females and black males. Under-representation is observed across the majority of SEER registries, with the highest amount of under representation in Utah and New Mexico. Under-representation of SEER data compared with US data is noticeably greater among tobacco-related cancers, particularly in Utah and New Mexico.
CONCLUSION: For certain cancer sites, particularly tobacco-related cancers, the SEER coverage population is not representative of the U.S. population.

Entities:  

Mesh:

Year:  2004        PMID: 15801487     DOI: 10.1007/s10552-004-1324-5

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  33 in total

1.  Relative survival analysis using the Centers for Disease Control and Prevention's National Program of Cancer Registries Surveillance System Data, 2000-2007.

Authors:  Reda J Wilson; A Blythe Ryerson; Kevin Zhang; Xing Dong
Journal:  J Registry Manag       Date:  2014

2.  Trends in incidence of oral and pharyngeal carcinoma in Florida: 1981-2008.

Authors:  Susan P McGorray; Yi Guo; Henrietta Logan
Journal:  J Public Health Dent       Date:  2011-09-19       Impact factor: 1.821

3.  The past, present, and future of cancer incidence in the United States: 1975 through 2020.

Authors:  Hannah K Weir; Trevor D Thompson; Ashwini Soman; Bjørn Møller; Steven Leadbetter
Journal:  Cancer       Date:  2015-02-03       Impact factor: 6.860

4.  Next steps to improve disparities in lung cancer treatment clinical trial enrollment.

Authors:  Leah L Zullig; William R Carpenter; Christina D Williams
Journal:  Ann Transl Med       Date:  2017-03

5.  Trends in incidence and survival of pediatric and adolescent patients with germ cell tumors in the United States, 1975 to 2006.

Authors:  Jenny N Poynter; James F Amatruda; Julie A Ross
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

6.  Poorer survival outcomes for male breast cancer compared with female breast cancer may be attributable to in-stage migration.

Authors:  Jennifer L Gnerlich; Anjali D Deshpande; Donna B Jeffe; Susmitha Seelam; Eric Kimbuende; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2010-12-14       Impact factor: 5.344

7.  Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008.

Authors:  S Jane Henley; Theodore C Larson; Manxia Wu; Vinicius C S Antao; Mary Lewis; Germania A Pinheiro; Christie Eheman
Journal:  Int J Occup Environ Health       Date:  2013 Jan-Mar

8.  How generalizable are the SEER registries to the cancer populations of the USA?

Authors:  Tzy-Mey Kuo; Lee R Mobley
Journal:  Cancer Causes Control       Date:  2016-07-21       Impact factor: 2.506

9.  Incidence of intracranial germ cell tumors by race in the United States, 1992-2010.

Authors:  Jenny N Poynter; Rachel Fonstad; Jakub Tolar; Logan G Spector; Julie A Ross
Journal:  J Neurooncol       Date:  2014-08-03       Impact factor: 4.130

10.  Skeletal Plasmacytoma: progression of disease and impact of local treatment; an analysis of SEER database.

Authors:  Muhammad Umar Jawad; Sean P Scully
Journal:  J Hematol Oncol       Date:  2009-09-24       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.